Kevin Wood1, Jason J Luke2. 1. University of Chicago Comprehensive Cancer Center, 5841 S. Maryland Ave. MC2115, Chicago, IL, 60637, USA. 2. University of Chicago Comprehensive Cancer Center, 5841 S. Maryland Ave. MC2115, Chicago, IL, 60637, USA. jluke@medicine.bsd.uchicago.edu.
Abstract
PURPOSE OF REVIEW: The therapeutic landscape for metastatic melanoma has been revolutionized in recent years. This review will discuss existing evidence for therapeutic approaches for BRAF-mutated metastatic melanoma. RECENT FINDINGS: Clinical trials involving combined BRAF/MEK inhibition with either vemurafenib plus cobimetinib or dabrafenib plus trametinib have shown improved overall survival compared to monotherapy with BRAF inhibitors alone. In a subset of patients with good prognostic factors, long-term clinical benefit has been noted. Simultaneously, developments in immunotherapy have suggested long-lasting survival for some patients. In advanced BRAF-mutated melanoma, both BRAF/MEK inhibition and immunotherapy agents show improved overall survival and, in a small population of patients, prolonged and long-term benefit as compared to standard chemotherapy. Trials are currently underway evaluating sequencing of these therapies and the safety of targeted therapy plus immunotherapy combinations.
PURPOSE OF REVIEW: The therapeutic landscape for metastatic melanoma has been revolutionized in recent years. This review will discuss existing evidence for therapeutic approaches for BRAF-mutated metastatic melanoma. RECENT FINDINGS: Clinical trials involving combined BRAF/MEK inhibition with either vemurafenib plus cobimetinib or dabrafenib plus trametinib have shown improved overall survival compared to monotherapy with BRAF inhibitors alone. In a subset of patients with good prognostic factors, long-term clinical benefit has been noted. Simultaneously, developments in immunotherapy have suggested long-lasting survival for some patients. In advanced BRAF-mutated melanoma, both BRAF/MEK inhibition and immunotherapy agents show improved overall survival and, in a small population of patients, prolonged and long-term benefit as compared to standard chemotherapy. Trials are currently underway evaluating sequencing of these therapies and the safety of targeted therapy plus immunotherapy combinations.
Authors: Caroline Robert; Boguslawa Karaszewska; Jacob Schachter; Piotr Rutkowski; Andrzej Mackiewicz; Daniil Stroiakovski; Michael Lichinitser; Reinhard Dummer; Florent Grange; Laurent Mortier; Vanna Chiarion-Sileni; Kamil Drucis; Ivana Krajsova; Axel Hauschild; Paul Lorigan; Pascal Wolter; Georgina V Long; Keith Flaherty; Paul Nathan; Antoni Ribas; Anne-Marie Martin; Peng Sun; Wendy Crist; Jeff Legos; Stephen D Rubin; Shonda M Little; Dirk Schadendorf Journal: N Engl J Med Date: 2014-11-16 Impact factor: 91.245
Authors: John A Jakob; Roland L Bassett; Chaan S Ng; Jonathan L Curry; Richard W Joseph; Gladys C Alvarado; Michelle L Rohlfs; Jessie Richard; Jeffrey E Gershenwald; Kevin B Kim; Alexander J Lazar; Patrick Hwu; Michael A Davies Journal: Cancer Date: 2011-12-16 Impact factor: 6.860
Authors: Georgina V Long; Uwe Trefzer; Michael A Davies; Richard F Kefford; Paolo A Ascierto; Paul B Chapman; Igor Puzanov; Axel Hauschild; Caroline Robert; Alain Algazi; Laurent Mortier; Hussein Tawbi; Tabea Wilhelm; Lisa Zimmer; Julie Switzky; Suzanne Swann; Anne-Marie Martin; Mary Guckert; Vicki Goodman; Michael Streit; John M Kirkwood; Dirk Schadendorf Journal: Lancet Oncol Date: 2012-10-08 Impact factor: 41.316
Authors: James Larkin; Michele Del Vecchio; Paolo A Ascierto; Ivana Krajsova; Jacob Schachter; Bart Neyns; Enrique Espinosa; Claus Garbe; Vanna Chiarion Sileni; Helen Gogas; Wilson H Miller; Mario Mandalà; Geke A P Hospers; Ana Arance; Paola Queirolo; Axel Hauschild; Michael P Brown; Lada Mitchell; Luisa Veronese; Christian U Blank Journal: Lancet Oncol Date: 2014-02-27 Impact factor: 41.316
Authors: Reinhard Dummer; Simone M Goldinger; Christian P Turtschi; Nina B Eggmann; Olivier Michielin; Lada Mitchell; Luisa Veronese; Paul René Hilfiker; Lea Felderer; Jeannine D Rinderknecht Journal: Eur J Cancer Date: 2013-11-29 Impact factor: 9.162
Authors: Antoni Ribas; Rene Gonzalez; Anna Pavlick; Omid Hamid; Thomas F Gajewski; Adil Daud; Lawrence Flaherty; Theodore Logan; Bartosz Chmielowski; Karl Lewis; Damien Kee; Peter Boasberg; Ming Yin; Iris Chan; Luna Musib; Nicholas Choong; Igor Puzanov; Grant A McArthur Journal: Lancet Oncol Date: 2014-07-15 Impact factor: 41.316
Authors: Douglas B Johnson; Keith T Flaherty; Jeffrey S Weber; Jeffrey R Infante; Kevin B Kim; Richard F Kefford; Omid Hamid; Lynn Schuchter; Jonathan Cebon; William H Sharfman; Robert R McWilliams; Mario Sznol; Donald P Lawrence; Geoffrey T Gibney; Howard A Burris; Gerald S Falchook; Alain Algazi; Karl Lewis; Georgina V Long; Kiran Patel; Nageatte Ibrahim; Peng Sun; Shonda Little; Elizabeth Cunningham; Jeffrey A Sosman; Adil Daud; Rene Gonzalez Journal: J Clin Oncol Date: 2014-10-06 Impact factor: 44.544
Authors: Douglas B Johnson; Alexander M Menzies; Lisa Zimmer; Zeynep Eroglu; Fei Ye; Shilin Zhao; Helen Rizos; Antje Sucker; Richard A Scolyer; Ralf Gutzmer; Helen Gogas; Richard F Kefford; John F Thompson; Jürgen C Becker; Carola Berking; Friederike Egberts; Carmen Loquai; Simone M Goldinger; Gulietta M Pupo; Willy Hugo; Xiangju Kong; Levi A Garraway; Jeffrey A Sosman; Antoni Ribas; Roger S Lo; Georgina V Long; Dirk Schadendorf Journal: Eur J Cancer Date: 2015-11-19 Impact factor: 9.162
Authors: Dennie T Frederick; Adriano Piris; Alexandria P Cogdill; Zachary A Cooper; Cecilia Lezcano; Cristina R Ferrone; Devarati Mitra; Andrea Boni; Lindsay P Newton; Chengwen Liu; Weiyi Peng; Ryan J Sullivan; Donald P Lawrence; F Stephen Hodi; Willem W Overwijk; Gregory Lizée; George F Murphy; Patrick Hwu; Keith T Flaherty; David E Fisher; Jennifer A Wargo Journal: Clin Cancer Res Date: 2013-01-10 Impact factor: 12.531
Authors: James Larkin; David Minor; Sandra D'Angelo; Bart Neyns; Michael Smylie; Wilson H Miller; Ralf Gutzmer; Gerald Linette; Bartosz Chmielowski; Christopher D Lao; Paul Lorigan; Kenneth Grossmann; Jessica C Hassel; Mario Sznol; Adil Daud; Jeffrey Sosman; Nikhil Khushalani; Dirk Schadendorf; Christoph Hoeller; Dana Walker; George Kong; Christine Horak; Jeffrey Weber Journal: J Clin Oncol Date: 2017-07-03 Impact factor: 44.544
Authors: Kimberley Hanson; Stephen D Robinson; Karamallah Al-Yousuf; Adam E Hendry; Darren W Sexton; Victoria Sherwood; Grant N Wheeler Journal: Oncotarget Date: 2017-12-17
Authors: Sarah Rohde; Tobias Lindner; Stefan Polei; Jan Stenzel; Luise Borufka; Sophie Achilles; Eric Hartmann; Falko Lange; Claudia Maletzki; Michael Linnebacher; Änne Glass; Sarah Marie Schwarzenböck; Jens Kurth; Alexander Hohn; Brigitte Vollmar; Bernd Joachim Krause; Robert Jaster Journal: Oncotarget Date: 2017-07-15